• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1280702 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ t2 v0 a: c$ d0 m/ uNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
* _. V8 d. Y3 ]' S$ q+ Author Affiliations
# f7 j1 j7 d3 k% _4 w0 w) T# B
: i; d5 c: Z3 d! s1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
" x9 G( G& K& z/ n2 W2 s+ n2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan   D0 h+ _  p5 x: c, i" H
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 0 ?9 Z- T- K$ q& I8 R
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) \( E9 {( ?) `! Y$ C& A
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. I& d) L, R  s6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
3 l( _% ?7 m5 O4 ]2 P# d3 r$ \. u7Kinki University School of Medicine, Osaka 589-8511, Japan 5 ^6 {3 U+ P0 _; N" I9 N& u2 {
8Izumi Municipal Hospital, Osaka 594-0071, Japan
2 P' v" n5 l, u1 W9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
* }$ g6 u8 k8 p5 ]/ A% I6 rCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
$ i4 O& Y* d8 I7 m! d4 R) J( fAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 4 Q* t6 p( o6 u" m9 z
7 d" W" e. ~+ G+ j+ g0 M
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type / ]' z$ A+ q5 X7 s/ i* ^

7 w" w8 w# e9 i& ?% `Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
$ H+ W/ C# ~4 |5 _; o
/ b! P; V1 o. r: e- G( U; L2 P7 z3 oAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  : c$ {3 z( U4 r' Q3 N3 K; w! ^4 M
- g, Z9 A, _* K; Q. p$ t$ Y* u
Published online on: Thursday, December 1, 2011
; @! s) q# j) X) H4 e/ f0 p$ D
  p: {. U8 U" c8 c+ M/ w" ]Doi: 10.3892/ol.2011.507 3 G" e- b) ?( G: Z4 f
, E# i( ^( r2 \* _0 W
Pages: 405-410 % a9 p, x3 G. n% i. `2 }" I% ?
1 X, [+ g$ |1 W5 Z% k5 Q
Abstract:  T6 h& j5 u" n: K) m
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.3 T3 I! k5 l9 L& ]! d8 N2 l! n
) [3 p1 M. u6 h- I
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
) f  u) R, `3 n9 |1 dF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 ) {4 R* k0 k$ p6 V3 J
+ Author Affiliations
: [, n2 I: R2 l1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu # s- d# F( A% w' x" j
2Department of Thoracic Surgery, Kyoto University, Kyoto * ~: i/ G$ S" S6 U
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
3 O' _' I) I# @4 M; Y8 r8 ^&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 6 y% X3 u/ V' z
Received September 3, 2010.
! i; R' p4 m& S) U; LRevision received November 11, 2010. 0 b" Q) E2 |  g+ r- i
Accepted November 17, 2010.
6 k  e' i& t# Q, o1 U2 k$ ~Abstract
- Q) Q6 D2 [3 _$ T" u  _  U0 nBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 8 {$ J2 b" j& ?8 B
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
/ M, X: ~; F: r' K* x9 E! _) H% U6 L& @Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. % I3 }7 t( U9 J4 t/ y% Z9 s
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
1 C5 w3 s+ X  a
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。5 r) H* A/ q6 V# b% x. W
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?2 M0 G# ?; m, L: [1 V
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy( F3 u' F* }3 d& C; ?( B
http://clinicaltrials.gov/ct2/show/NCT01523587
* v! N2 C, i" Y2 r) z
" L3 F- J7 Z- @- u. f# z  [BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC, v6 E% W$ M' W4 {4 g# D: t# t5 z
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 2 Z$ K8 B2 b6 F) X" N

) j  |0 P4 v& K. t; G从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 P3 G5 k7 z/ C
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 & s; g% L0 n9 F/ j0 [7 p& v+ H
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。. Y; j  u3 U, r8 V, W$ X6 `
至今为止,未出 ...

6 u+ {* f( {5 c4 x& E# n7 o: n没有副作用是第一追求,效果显著是第二追求。+ ]5 r$ Q+ G3 O! e% u$ U8 M2 ^
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表